GI-MAP Dysbiosis Treatment: A Practitioner's Guide

Dysbiosis detected on GI-MAP doesn't have to feel like decoding a foreign language. Whether you're interpreting your own results or explaining them to patients, this guide breaks down what dysbiosis actually means, how to interpret "stealth pathogens," what beta-glucuronidase reveals about gut health, and what treatment approaches actually move the needle.

Part of the GI-MAP Interpretation Series — [[→ Pillar: GI-MAP Interpretation]] | [[→ Hub: Lab Interpretation]] | Work with a practitioner →

---

---

What is dysbiosis as shown on GI-MAP?

Dysbiosis refers to an imbalance in the gut microbiome—where beneficial and opportunistic microbes shift out of their normal ratio. On GI-MAP, this shows up as deviations from expected ranges across both commensal bacteria and opportunistic organisms.

The critical difference from older stool tests: GI-MAP uses qPCR DNA technology rather than traditional culture-based methods. This detects specific microbial DNA at the species and strain level, providing quantitative counts—not just "present or absent." A study in Gut Pathogens found that qPCR-based stool testing identifies dysbiosis with significantly higher sensitivity than conventional culture methods (Vázquez-Castellanos et al., 2015; PMID: 25973666).

On a GI-MAP report, dysbiosis typically appears as:

• Elevated opportunistic pathogens (e.g., certain E. coli strains, Enterococcus, Klebsiella)
• Depleted beneficial bacteria (e.g., Lactobacillus, Bifidobacterium, Faecalibacterium prausnitzii)
• Abnormal commensal markers outside established reference ranges
• Fungal overgrowth (Candida spp., Saccharomyces cerevisiae)

The pattern matters more than any single number. A patient with low Lactobacillus but otherwise normal markers has a fundamentally different dysbiosis profile than someone with elevated Campylobacter and high Enterococcus simultaneously. Treatment approaches differ accordingly—this is where clinical correlation earns its keep.

---

How do I interpret "stealth pathogens" on my GI-MAP?

"Stealth pathogens" is a clinical term for opportunistic microbes that may be present at low levels without triggering obvious acute illness. On GI-MAP, these often register as + or ++ (rather than +++) and may not correlate with dramatic symptoms—hence "stealth."

Common stealth pathogens seen on GI-MAP and their clinical implications:

Pathogen	Clinical Significance	Typical Treatment Approach
Campylobacter spp.	Low-grade inflammation, joint pain, fatigue	Antimicrobial herbs: berberine, oil of oregano
Yersinia enterocolitica	Digestive disturbances, autoimmune triggers	Antibacterial protocol + dietary removal
Enterotoxigenic E. coli	Gas, bloating, immune activation	Probiotic competition + antimicrobial support
Helicobacter pylori	Gastric symptoms, nutrient absorption issues	Eradication protocol if symptomatic
Clostridioides difficile toxins	Antibiotic-associated diarrhea, colitis risk	Immediate medical assessment if positive

The clinical question isn't just "is this pathogen present?"—it's "is this contributing to the patient's symptoms?"

A stealth pathogen at low levels in an asymptomatic patient may warrant watchful observation and retesting in 8–12 weeks. The same organism at any level in a patient with chronic fatigue, unexplained systemic inflammation, or active autoimmune activity often warrants a treatment trial.

Key principle: Correlate findings with clinical presentation. A positive Campylobacter result in a patient with chronic bloating, joint pain, and fatigue is highly actionable. The same result in someone without gut symptoms requires more careful clinical judgment.

---

What does beta-glucuronidase tell me about my gut?

Beta-glucuronidase is an enzyme produced by certain gut bacteria that cleaves glucuronic acid conjugates in the intestinal lumen. In practical terms: it can either help or significantly hinder detoxification and hormone metabolism depending on its activity level.

Why it matters: During phase II liver detoxification, hormones (especially estrogens) and toxins are conjugated to glucuronic acid for excretion. High beta-glucuronidase activity breaks these conjugates apart in the gut—releasing free estrogen and toxins back into circulation before they can be eliminated. This "deconjugation" is a key driver of estrogen dominance symptoms.

High beta-glucuronidase (>50 U/g) typically indicates:

• Increased estrogen reabsorption → potential hormonal symptoms (PMS, endometriosis, estrogen-dominant patterns)
• Altered phase II detoxification efficacy
• Often associated with dysbiosis, high-fat/low-fiber diets, and Western dietary patterns
• Elevated opportunistic bacterial activity driving enzyme production

Low beta-glucuronidase (<20 U/g) may suggest:

• Reduced overall bacterial activity
• Recent antibiotic exposure
• Microbiome depletion—less concern for estrogen reabsorption, but may reflect a depleted ecosystem

Research published in ACS Chemical Biology demonstrated that beta-glucuronidase enzymes from gut bacteria directly influence xenobiotic and hormone metabolism—with activity levels varying significantly by bacterial composition (Pollet et al., 2017; PMID: 28768550; PMC: PMC5533298).

Clinical tip: When beta-glucuronidase is elevated alongside dysbiosis, addressing the underlying microbiome imbalance often normalizes enzyme activity without requiring direct supplemental intervention. Calcium D-glucarate (a beta-glucuronidase inhibitor) can provide supportive benefit—but foundational work must target the dysbiotic ecosystem first. Supplement-only approaches without addressing root-cause dysbiosis produce inconsistent results.

---

What treatment options exist for GI-MAP dysbiosis?

The 5R Protocol is the gold-standard functional medicine framework for addressing GI-MAP-detected dysbiosis. The sequence matters—don't reinoculate before removing.

1. REMOVE

• Pathogens and opportunistic organisms identified on testing
• Dietary irritants: gluten, dairy, processed foods, alcohol, excess sugar
• Inflammatory triggers relevant to the individual's pattern

Antimicrobial herbs commonly used:

• Berberine (500 mg TID) — broad-spectrum antibacterial
• Oil of oregano (200 mg BID) — antifungal + antibacterial
• Allicin from garlic — H. pylori and gram-negative coverage
• Neem, wormwood — parasitic coverage if indicated

2. REPLACE

• Digestive enzymes (especially lipase when fat malabsorption markers are elevated)
• Betaine HCl trial for low stomach acid (hypochlorhydria)
• Bitters or gastric acid support if clinically indicated
• Ox bile support if bile acid markers are abnormal

3. REINOCULATE

• Probiotics selected by strain based on GI-MAP findings (not one-size-fits-all)
• Saccharomyces boulardii for antimicrobial-phase support and C. difficile risk reduction
• Prebiotic fibers (resistant starch, inulin, partially hydrolyzed guar gum) after acute antimicrobial phase
• Spore-forming probiotics (Bacillus strains) for more depleted or disrupted microbiomes

4. REPAIR

• L-glutamine powder (5 g daily) for intestinal epithelial support
• Zinc carnosine (30 mg) for mucosal integrity
• Bone broth, collagen peptides, omega-3 fatty acids for tissue repair
• Vitamin D3 if deficient (strong gut immune connection)
• Deglycyrrhizinated licorice (DGL) for gastric mucosal protection

5. REBALANCE

• Stress regulation: sleep hygiene, nervous system support, movement
• Long-term dietary maintenance: Mediterranean-style or low-FODMAP hybrid
• Environmental toxin reduction (plastics, pesticide exposure)
• Follow-up GI-MAP testing at 12–16 weeks to confirm resolution

Timeline expectations: Mild dysbiosis may resolve in 4–8 weeks. Chronic patterns, stealth pathogen eradication, or biofilm-associated organisms often require 12–16+ weeks with retesting to confirm.

---

How do I read my GI-MAP results like a practitioner?

GI-MAP reports are organized into distinct sections. Here's the shorthand for clinical interpretation:

Pathogens Section

• Bacterial, parasitic, viral, and fungal organisms requiring treatment
• Any detection warrants clinical correlation—treat based on pattern + symptom picture
• → [[→ GI-MAP Pathogens Guide]] for species-specific interpretation

Commensals (Beneficial Bacteria)

• Lactobacillus, Bifidobacterium, Enterococcus, Faecalibacterium prausnitzii, etc.
• Low levels across multiple species = significant depletion requiring reinoculation priority
• → [[→ GI-MAP Commensals Guide]] for restoration protocols

Immune Markers

• Secretory IgA (sIgA): Gut immune barrier function—low sIgA = compromised mucosal immunity
• Eosinophil Protein X: Allergenic and inflammatory activity indicator
• → [[→ GI-MAP Immunity Markers]] for interpretation thresholds

Digestion & Absorption

• Pancreatic elastase-1 (exocrine pancreatic function)
• Fat malabsorption markers (steatocrit, triglycerides)
• Gluten sensitivity markers if indicated
• → [[→ GI-MAP Digestion Markers]] for enzyme replacement guidance

Special Markers

• Beta-glucuronidase (see above)
• Occult blood — warrants medical follow-up if positive
• Calprotectin — intestinal inflammation marker; elevated = active mucosal inflammation

Pattern-reading principle: Don't cherry-pick one marker. Elevated beta-glucuronidase plus depleted beneficial bacteria plus fat malabsorption tells a fundamentally different treatment story than any single finding in isolation. The constellation is the diagnosis.

---

Case Example: Putting It All Together

Patient: 34-year-old female, presenting with chronic bloating, persistent fatigue, and irregular bowel movements × 18 months. Prior workup unremarkable.

GI-MAP Findings:

Marker	Result	Reference
Beta-glucuronidase	85 U/g	High (>50 U/g)
Lactobacillus spp.	Low	Depleted
Enterococcus spp.	Elevated	Opportunistic overgrowth
Campylobacter	+ (detected)	Stealth pathogen
Steatocrit (fat malabsorption)	Elevated	Impaired fat digestion
sIgA	Low-normal	Borderline immune depletion

Clinical Interpretation: The pattern suggests dysbiosis-driven beta-glucuronidase elevation (explaining potential hormonal symptoms), impaired fat digestion (contributing to bloating and fatigue), and a low-level Campylobacter infection that may be sustaining the inflammatory background. Low sIgA suggests the gut immune barrier needs support.

Treatment Protocol (Sequential 5R Application):

1. Remove (weeks 1–4): Berberine 500 mg TID + oil of oregano 200 mg BID for Campylobacter; eliminate gluten, dairy, alcohol
2. Replace (weeks 1–8): Full-spectrum digestive enzymes with lipase at meals; betaine HCl trial starting at 1 capsule per meal
3. Reinoculate (weeks 5–12): S. boulardii 250 mg BID during antimicrobial phase → Lactobacillus-dominant probiotic + prebiotic fiber post-week 4
4. Repair (weeks 1–12, ongoing): L-glutamine 5 g daily; zinc carnosine 30 mg daily; omega-3 2 g daily; vitamin D3 5,000 IU (per labs)
5. Rebalance: Low-FODMAP + Mediterranean hybrid diet; sleep protocol; stress reduction

Outcome at 8-week recheck: Bloating reduced ~70%; energy improved significantly; beta-glucuronidase normalized to 42 U/g; Campylobacter undetectable on repeat panel.

---

Quick Reference: What to Do When…

GI-MAP Finding	Priority Action
Stealth pathogen + matching symptoms	4–8 week antimicrobial herb protocol; follow full 5R
Low beneficial bacteria (multiple species)	Prioritize reinoculation; add prebiotic fiber
High beta-glucuronidase	Address dysbiosis first; consider calcium D-glucarate
Fat malabsorption elevated	Replace with lipase-containing enzymes; check bile acids
Low sIgA	Colostrum, vitamin A, stress reduction; protect immune barrier
Multiple abnormal findings	Sequence: Remove → Repair simultaneously → Reinoculate last
Positive occult blood or high calprotectin	Medical referral before proceeding with gut protocol

---

Looking Deeper

This article is part of the GI-MAP Interpretation Series:

• [[→ Pillar: GI-MAP Interpretation]] — Complete test overview, all sections, and clinical decision-making framework
• [[→ Hub: Lab Interpretation]] — All functional lab interpretation guides in one place
• [[→ GI-MAP Pathogens Guide]] — Pathogen-specific detection and treatment protocols
• [[→ GI-MAP Commensals Guide]] — Beneficial bacteria restoration and reinoculation strategies
• [[→ GI-MAP Immunity Markers]] — sIgA, eosinophil protein X, and mucosal immune health
• [[→ GI-MAP Digestion Markers]] — Pancreatic elastase, fat malabsorption, enzyme replacement

---

References

1. Vázquez-Castellanos JF, et al. "Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals." Mucosal Immunology. 2015; PMID: 25973666
2. Pollet RM, et al. "An Atlas of β-Glucuronidases in the Human Intestinal Microbiome." Structure. 2017; PMC: PMC5533298
3. Diagnostic Solutions Laboratory. GI-MAP Clinical Reference Guide. https://www.diagnosticsolutionslab.com/tests/gi-map
4. Nordic Labs. GI-MAP Interpretive Guide. https://nordic-labs.com/ProductPDF/split_NL-GI%20MAP%20Guide-02_3827.pdf

---

Final Thought

Dysbiosis on GI-MAP is a diagnostic finding, not a final verdict. The quantitative nature of qPCR testing gives you a baseline to measure against—and a treatment roadmap that matches the specific pattern you're seeing.

The question isn't whether to treat dysbiosis. It's whether the pattern explains the patient's symptoms and whether your intervention is proportionate to the clinical picture.

When you have both of those answers, treatment is straightforward.

---

Ready to Understand Your GI-MAP Results?

Working with a practitioner who knows how to read patterns—not just flag individual markers—changes outcomes.

Book a GI-MAP Interpretation Consultation →

Already have results and want to go deeper? Explore the full GI-MAP series or learn how HANS helps functional medicine practitioners document and interpret complex labs faster →.

Want to learn more about gut health testing first? Start with our [[→ Pillar: GI-MAP Interpretation|complete GI-MAP test overview]].